Table 4 Characteristics of DrotAA-treated adults with PF, MEN, or MD and experienced a serious bleeding event
Characteristic | During infusion | After infusion | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Relative day of event onset1 | 1 | 1 | 2 | 3 | 5 | 6 | 6 | 7 | 11 | 18 |
Bleeding event | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   ICH | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
   Fatal | No | No | No | No | Yes | No | No | No | Yes | No |
   DrotAA-related2 | Yes | No | No | No | Yes | Yes | No | Yes | No | No |
Disease category | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   PF | Yes | Yes | No | No | No | Yes | Yes | No | Yes | Yes |
   MEN | No | No | Yes | Yes | Yes | Yes | No | Yes | Yes | No |
   MD | Yes | No | Yes | No | No | Yes | No | No | No | Yes |
Baseline characteristics | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Age (years) | 19 | 20 | 47 | 67 | 73 | 24 | 41 | 77 | 51 | 40 |
   Protein C level (%) | 11 | NA | 11 | 68 | 55 | 79 | - | 52 | - | 24 |
   Platelet count | 38 | 58 | 154 | 102 | 93 | 30 | 136 | 56 | 11 | 51 |
   APTT (s) | 198 | 86.7 | 65.0 | 31.1 | - | 63.0 | - | 32.0 | - | 47 |
   PT (s) | 58.9 | 16.6 | - | 14.1 | - | - | 16.3 | - | 2.6 | - |
   Organ failure | 5 | NA | 2 | 1 | 3 | 3 | - | 1 | - | 4 |
   APACHE II score | 30 | NA | 20 | 23 | 24 | 26 | - | 20 | - | 25 |
   Hypertension | No | No | No | Yes | Yes | No | No | Yes | No | No |
SOFA3 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Platelet count | 38 | NA | 70 | 120 | 181 | 34 | NA | NA | NA | NA |
   Hematology SOFA score | 3 | NA | 2 | 1 | 0 | 3 | NA | NA | NA | NA |
   Hepatic SOFA score | 1 | NA | 1 | 0 | - | 2 | NA | NA | NA | NA |
   Renal SOFA score | 2 | NA | 2 | 0 | 0 | 0 | NA | NA | NA | NA |